Skip to main content

Table 2 Potential predictive factors and risk of SN metastases

From: Predictive factors for sentinel node metastases in primary invasive breast cancer: a population-based cohort study of 2552 consecutive patients

Determinants Category SN negative SN positive OR 95% CI OR 95% CIa
Screening No 719 343 1.00 1.00
Yes 1123 312 0.59(0.49–0.70) 0.63(0.51–0.80)
Unknown 39 16 0.86(0.48–1.57) 0.88(0.46–1.66)
Age ≤ 50 337 162 1.00 1.00
51–74 1290 412 0.67(0.53–0.82) 0.92(0.63–1.37)
≥ 75 254 97 0.80(0.59–1.08) 0.70(0.42–1.11)
Menopause Status Pre 348 164 1.00 1.00
Post < 5 years 168 60 0.76(0.53–1.08) 0.98(0.62–1.53)
Post ≥ 5years 1299 422 0.69(0.56–0.86) 0.82(0.56–1.22)
Unknown 66 25 0.80(0.49–1.32) 0.89(0.50–1.53)
Tumor size T1 1138 367 1.00 1.00
T2 346 213 1.91(1.56–2.34) 1.84(1.47–2.33)
T3 and T4 13 12 2.87(1.30–6.32) 2.56(1.07–6.09)
Unknown 384 79 0.63(0.49–0.83) 0.67(0.50–0.93)
Tumor type Ductal 1325 542 1.00 1.00
D and L 35 17 1.19(0.66–2.13) 1.01 (0.54–1.90)
Lobular 217 88 1.00(0.77–1.30) 0.87(0.64–1.20)
Others 306 24 0.20(0.12–0.30) 0.29(0.18–0.46)
Histological grade I 488 134 1.00 1.00
II 807 305 1.37(1.09–1.73) 1.02(0.80–1.31)
III 563 227 1.46(1.14–1.87) 1.10(0.82–1.50)
Unknown 23 5 0.79(0.29–2.12) 1.40(0.46–4.31)
Estrogen receptor Positive 1538 606 1.00 1.00
Negative 218 61 0.71(0.52–0.96) 0.64(0.42–0.99)
Unknown 125 4 0.09(0.03–0.22) 0.06(0.00–0.82)
Progesterone receptor Positive 1320 531 1.00 1.00
Negative 436 135 0.77(0.61–0.96) 0.78(0.56–1.07)
Unknown 125 5 0.10(0.04–0.24) 3.80(0.30–47.42)
Her-2 status Negative 1041 423 1.00 1.00
Positive 174 66 0.93(0.69–1.27) 0.84(0.60–1.20)
Unknown 666 182 0.68(0.56–0.82) 0.98(0.78–1.24)
Multifocality No 1184 386 1.00 1.00
Yes 208 144 2.12(1.67–2.70) 1.90(1.45–2.47)
Unknown 489 141 0.89(0.71–1.10) 0.86(0.67–1.09)
Vascular invasion No 1056 268 1.00 1.00
  Yes 87 97 4.40(3.20–6.04) 3.74(2.66–5.27)
  Unknown 738 306 1.63(1.36–1.98) 2.10(1.68–2.62)
  1. aAdjusted including screening, age, menopause status, tumor size, tumor type, histological grade, estrogen status, progesterone status, Her-2 status, multifocality, and vascular invasion